Head to head
VK2735 against Orforglipron
Both are pitched at people who want to swallow rather than inject, but only one of them is approved and only one of them is a small molecule. VK2735 has an oral form that completed phase 2 and an injectable form in phase 3.
Column A
VK2735VK2735 (dual GLP-1 / GIP agonist)
Viking Therapeutics' dual GLP-1 and GIP agonist in Phase 3 as an injection, with an oral version showing rapid early weight loss.
Column B
OrforglipronOrforglipron (Foundayo, oral non-peptide GLP-1 agonist)
A once-daily GLP-1 pill rather than a shot, a small molecule rather than a peptide, FDA-approved on April 1, 2026 as Foundayo for weight management.
Side by side, on the facts we can check
| Attribute | VK2735 | Orforglipron |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational (Phase 3 VANQUISH-1 and VANQUISH-2 fully enrolled; oral form completed Phase 2) | FDA-approved April 1, 2026 as Foundayo for chronic weight management (boxed thyroid C-cell warning) |
| Half-life | Supports weekly dosing (injectable) | ~29-49 hours |
| Molecular weight | Not disclosed | ~735 Da |
| Mechanism | Agonizes both the GLP-1 and GIP receptors to enhance insulin secretion, reduce appetite, and slow gastric emptying. | Activates the GLP-1 receptor as an orally available small molecule, reducing appetite and improving glucose-dependent insulin secretion. |
| Human studies cited | 3 | 5 |
| Legal status, US | Investigational, not approved | FDA-approved (Foundayo, chronic weight management), prescription only |
Frequently asked questions
What is the difference between VK2735 and Orforglipron?
VK2735: Viking Therapeutics' dual GLP-1 and GIP agonist in Phase 3 as an injection, with an oral version showing rapid early weight loss. Orforglipron: A once-daily GLP-1 pill rather than a shot, a small molecule rather than a peptide, FDA-approved on April 1, 2026 as Foundayo for weight management.
Which has stronger research evidence, VK2735 or Orforglipron?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the VK2735 profile were human work, against 5 of 5 for Orforglipron. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are VK2735 and Orforglipron FDA-approved?
VK2735: Investigational (Phase 3 VANQUISH-1 and VANQUISH-2 fully enrolled; oral form completed Phase 2). Orforglipron: FDA-approved April 1, 2026 as Foundayo for chronic weight management (boxed thyroid C-cell warning).
Related posts
Blog articles that cover VK2735 or Orforglipron, newest first.
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
- Metabolic / Sep 8, 2026 / 9 minRetatrutide vs Tirzepatide vs Semaglutide vs the Pill: The 2026 GLP-1 Field Guide
- Regulation / Sep 8, 2026 / 9 minFDA Peptide Status in 2026: The Category 2 Removals, the July Votes, and What Actually Changed
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.